Clinical Trial News and Research

RSS

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the third quarter ended September 30, 2010.

28 Oct 2010

Reuters examines development progress of microbicide gel to prevent HIV

Reuters reports that the developers of a vaginal microbicide gel containing the antiretroviral tenofovir, which has been found to reduce "HIV infections in women by 39 percent," said the FDA last week granted fast-track approval designation to the gel.

28 Oct 2010

Endologix announces definitive agreement to acquire Nellix

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs).

28 Oct 2010

InVivo Therapeutics completes reverse merger with InVivo

InVivo Therapeutics Corporation a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp.

28 Oct 2010

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it received approval from the State Food and Drug Administration ("SFDA") Ethics Committee to commence Phase I human clinical trials of R-Bambuterol Hydrochloride, the Company's proprietary drug candidate for the treatment of asthma.

28 Oct 2010

Endologix 2010 third quarter total revenue increases 30% to $17.9 million

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010.

28 Oct 2010

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2010.

27 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

Survey shows Americans are unaware about causes of lung cancer

Men and women worry about prostate and breast cancer, yet the number one cancer killer in the United States – lung cancer – isn't on their radar. According to a survey released today by the National Lung Cancer Partnership, Americans know little about lung cancer's causes, symptoms and the number of lives it takes compared to other cancers.

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

HIFU technology effective for treating metastatic liver cancer

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of the first phase of the clinical protocol aimed at evaluating High Intensity Focused Ultrasound (HIFU) technology in patients with metastatic liver cancer. HIFU has the potential to destroy liver tumors through ablation and to reduce bleeding during surgery.

27 Oct 2010

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.

27 Oct 2010

PPD and VirtualScopics partner to provide medical imaging services

PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

26 Oct 2010

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

26 Oct 2010

Neurologix holds license for gene therapy to treat severe depression

Neurologix, Inc. today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.

26 Oct 2010

CorMatrix's ECM technology reduces postoperative atrial fibrillation in CABG patients

CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that a retrospective study demonstrated that reconstructing the pericardium using ECM Technology in patients undergoing primary isolated coronary artery bypass grafting (CABG) contributed to a statistically significant and clinically meaningful reduction in the rate of new onset postoperative atrial fibrillation.

26 Oct 2010

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.

26 Oct 2010

Dual antiplatelet therapy study expanded into Australia and New Zealand

The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into Australia and New Zealand. Professor Ian Meredith, MBBS, Ph.D., interventional cardiologist at MonashHeart in Melbourne, Australia and National Coordinating Investigator for the DAPT Study in Australia, was the first Pacific Rim investigator to enroll patients into the study.

26 Oct 2010

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today the results of a clinical trial of its investigational Fluzone Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

Clinical Trial News and Research

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

Reuters examines development progress of microbicide gel to prevent HIV

Endologix announces definitive agreement to acquire Nellix

InVivo Therapeutics completes reverse merger with InVivo

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Endologix 2010 third quarter total revenue increases 30% to $17.9 million

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Survey shows Americans are unaware about causes of lung cancer

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

HIFU technology effective for treating metastatic liver cancer

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

PPD and VirtualScopics partner to provide medical imaging services

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Neurologix holds license for gene therapy to treat severe depression

CorMatrix's ECM technology reduces postoperative atrial fibrillation in CABG patients

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Dual antiplatelet therapy study expanded into Australia and New Zealand

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer